by Peter Ciszewski | Dec 28, 2018
Rami Levin, President of North America for Swedish Orphan Biovitrum (SOBI) discusses his company’s recent FDA approval, Sobi’s commitment to the rare disease community, and how Sobi is growing its presence in North America. We sat down with Rami Levin at...
by Peter Ciszewski | Dec 27, 2018
Mohamad Mohty, MD, PhD, Professor of Hematology at Sorbonne University and Head of the Hematology and Cellular Therapy Department at the Saint Antoine Hospital in Paris, discusses EBV+ PTLD is an aggressive lymphoma that occurs following bone marrow transplant...
by Peter Ciszewski | Dec 26, 2018
The U.S. Food and Drug Administration (FDA) has accepted for review a new drug application (NDA) for Edsivo for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. The FDA also granted a priority...
by Peter Ciszewski | Dec 26, 2018
Vanessa Vogel-Farley, Executive Director, Dup15q Alliance discusses Dup15q syndrome, the common name for chromosome 15q11.2-q13.1 duplication syndrome. Dup15q syndrome is the common name for chromosome 15q11.2-q13.1 duplication syndrome. This is a neurodevelopmental...
by Peter Ciszewski | Dec 25, 2018
The 2017 Emmy-nominated Rare in Common documentary gave people from the rare disease community an opportunity to tell their stories. Today, the storytelling has expanded to the world of audio with the Rare in Common podcast.
